Optoacoustic skin mesoscopy opens a window to systemic effects of diabetes

Hailong He; Nikolina-Alexia Fasoula; Angelos Karlas; Murad Omar; Juan Aguirre; Jessica Lutz; Michael Kallmayer; Martin Füchtenbusch; Hans-Henning Eckstein; Anette-Gabriele Ziegler; Vasilis Ntziachristos

doi:10.1101/2020.06.29.20142273

Abstract

Diabetes mellitus affects the microvasculature of several organs, including the eyes, heart, brain, kidneys and skin. The skin is the most accessible organ and could offer a window for detecting diabetes-related systemic effects on the microvasculature. However, assessment of skin microvasculature is typically performed based on invasive histological analysis, which is a method that is not well suited for disease monitoring and application to large populations. We introduce ultra-wide band raster-scan optoacoustic mesoscopy (RSOM) for precise, non-invasive assessment of diabetes-related changes in the dermal microvasculature and skin micro-anatomy, resolved with unprecedented sensitivity and detail without the need of contrast agents. Based on this novel contrast, we investigated whether RSOM could impart a new concept in diabetes healthcare, offering characterization of systemic effects of the disease. We applied pretibial RSOM to 72 patients with diabetes, grouped according to disease complications, and 20 age-matched healthy volunteers. We extracted six label-free optoacoustic biomarkers, including dermal microvasculature density, total dermal blood volume and epidermal parameters. We study the effects of diabetes on these parameters as a function of disease severity and find strong statistically significant differences between microvasculature parameters and diabetes progression. We discuss how RSOM label-free biomarkers can lead to a quantitative assessment of the systemic effects of diabetes, complementing the qualitative assessment allowed by current clinical metrics and possibly, in the future, enable a more precise scoring system capturing the gradual evolution of disease.

Competing Interest Statement

Vasilis Ntziachristos is a founder and consultant for i3

Funding Statement

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 687866 (INNODERM), from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme under grant agreement No 694968 (PREMSOT) and from Helmholtz Zentrum Muenchen through Physician Scientists for Groundbreaking Projects, in part by the Helmholtz Association of German Research Center, through the Initiative and Networking Fund, i3 (ExNet-0022-Phase2-3).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Approval for the study was provided by the local Ethics Committee of the Hospital of the Technical University of Munich. Klinikum Rechts der Isar, Ismaninger Str. 22, 81675 Muenchen.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes